
Somarant10 mg
Incepta Pharmaceuticals Ltd.
Suvorexant is indicated for the treatment of insomnia in adults, characterized by difficulty with sleep onset and/or sleep maintenance.
Suvorexant is indicated for the treatment of insomnia in adults, characterized by difficulty with sleep onset and/or sleep maintenance.
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once nightly, taken within 30 minutes of going to bed |
| Maximum dose | 20 mg once nightly if the lower dose is well tolerated but not effective |
| Timing requirement | Only when at least 7 hours are available before the planned time of waking |
Recommended dose is 15 mg once nightly (may be increased to a maximum of 20 mg if needed and tolerated), using the same timing precautions as in younger adults.
No dose adjustment is required in patients with renal impairment, including those with severe renal impairment.
See Drug Interactions section for required dose modifications with concomitant CYP3A4 inhibitors.
Not established; see Pediatric Uses section.
Suvorexant is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.